New Maryland Waiver Must Encourage Innovation

In an Op-Ed in the Baltimore Sun, John Colmers, a Sr. VP at Johns Hopkins Medicine and a member of the Health Services Cost Review Commission, describes how successful Maryland's unique "waiver" program  has been. However, he cautions, as we institute the next phase of the program, specific situations unique to our academic medical institutions must be considered. He writes in part:

"By the end of this year, Maryland must submit a blueprint to the federal government for the next phase of the waiver. Without a doubt, it must include plans to enhance patient care and create mechanisms to improve care coordination for Maryland's sickest patients. At the same time, however, it must be designed so as to permit our academic medical centers to thrive in the global market for innovation."